Video abstract of review “Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis” published in the open access journal Core Evidence by Eshtiaghi P, Gooderham MJ.
Introduction: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with
complex immunopathogenesis characterized by a dominant TH2 response. Dupilumab is an
interleukin (IL)-4 receptor alpha antagonist that subsequently blocks IL-4 and IL-13 signaling.
It has recently been approved for the treatment of adult patients with moderate-to-severe AD
whose current treatment options are limited.
Aim: This article reviews the evidence of clinical efficacy, safety, and patient-reported outcome
(PRO) measures from Phase I–III trials of dupilumab in adult patients with moderateto-
severe AD.
Evidence review: Results from clinical trials of dupilumab in adults with moderate-to-severe
AD have shown that weekly or biweekly dupilumab injections significantly improve clinical and
PROs. Transcriptome and serum analyses also found that dupilumab significantly modulates the
AD molecular signature and other TH2-associated biomarkers, compared with placebo. Additionally,
concomitant use of dupilumab with topical corticosteroids (TCS) results in a greater
improvement in signs and symptoms of AD than with dupilumab use alone. Throughout the
trials, common adverse events were headaches, conjunctivitis, and injection site reactions. These
were consistently mild–moderate and occurred with similar frequency between the treatment
and placebo groups.
Place in therapy: In adult patients with moderate-to-severe refractory AD, monotherapy or
concomitant use of dupilumab with TCS holds great promise to significantly improve clinical
outcomes and quality of life of the patient. Ongoing studies of dupilumab will help determine
the clinical efficacy and safety profile of its long-term use. Finally, further economic evidence
is warranted to compare the long-term costs and benefits of dupilumab with other currently
available treatments for moderate-to-severe AD.
Read the Review paper here:
source
